Last updated: 11/07/2018 16:15:47
A multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous Org31540/SR90107A with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement (Pentathlon).
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous Org31540/SR90107A with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement (Pentathlon).
Trial description: A multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous Org31540/SR90107A with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement (Pentathlon).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Turpie AG. Dose-dependent activity of Arixtra in the prophylaxis of deep vein thrombosis following total hip replacement: Rationale of dose selection with a Phase II study (Pentathlon). N Engl J Med 2001; 344: 619-25.
Medical condition
Thrombosis, Venous
Product
fondaparinux sodium
Collaborators
Not applicable
Study date(s)
November 1996 to March 1998
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1998-03-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website